Monopar Therapeutics Reports Q1 2026 Financials, Extends Cash Runway to End of 2027, ALXN1840 NDA Expected Mid-2026

summarizeSummary

Monopar Therapeutics reported Q1 2026 results, showing increased R&D spend and a cash runway through December 2027, with its lead candidate ALXN1840's NDA submission now targeted for mid-2026.

check_boxKey Events

• Strong Cash Position and Extended Runway

  The company reported $137.5 million in cash, cash equivalents, and investments as of March 31, 2026, and estimates these funds will be sufficient to meet obligations through December 31, 2027.

• Increased Research and Development Expenses

  R&D expenses significantly increased to $3.49 million for Q1 2026, up from $1.64 million in Q1 2025, reflecting active advancement of its clinical programs.

• ALXN1840 NDA Submission Timeline Update

  The NDA submission for ALXN1840, its lead candidate for Wilson disease, is now expected in mid-2026, following continued dialogue with the FDA.

• Ongoing Radiopharmaceutical Pipeline Progress

  Monopar continues to advance its MNPR-101-Zr (Phase 1 imaging) and MNPR-101-Lu (Phase 1a therapeutic) clinical trials, with MNPR-101-Ac in late preclinical development.

auto_awesomeAnalysis

Monopar Therapeutics' latest quarterly report provides an updated financial snapshot and key pipeline developments. The company maintains a strong cash position, extending its operational runway through December 2027, which is crucial for a clinical-stage biotech. The increased R&D expenses reflect active development across its ALXN1840 and radiopharmaceutical programs. While the ALXN1840 NDA submission is now anticipated in mid-2026, indicating a slight delay, the ongoing positive clinical data and constructive dialogue with the FDA suggest continued progress towards regulatory approval.